RGNX Earnings & Financial Statements
REGENXBIO Inc.
$8.17
+$0.58(+7.57%)
36
Overall
40
Value
18
Tech
50
Quality
Market Cap
$501.37M
Volume
850.99K
52W Range
$5.46 - $16.19
Target Price
$24.42
RGNX earnings and financial statements: REGENXBIO Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RGNX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $170.44M | $83.33M | $90.24M | $112.72M | $470.35M |
| Cost of revenue | $20.30M | $33.57M | $37.21M | $54.55M | $51.83M |
| Operating income | -$161.20M | -$233.35M | -$268.13M | -$262.88M | $159.98M |
| EBITDA | -$133.27M | -$198.24M | -$246.35M | -$244.25M | $177.09M |
| Net income | -$193.88M | -$227.10M | -$263.49M | -$280.32M | $127.84M |
| EPS (diluted) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $453.03M | $465.99M | $573.97M | $833.27M | $1.11B |
| Total liabilities | $350.30M | $206.34M | $262.23M | $317.07M | $349.61M |
| Shareholders’ equity | $102.73M | $259.65M | $311.74M | $516.20M | $764.30M |
| Cash and equivalents | $34.47M | $57.53M | $34.52M | $96.95M | $345.21M |
| Long-term debt | $65.22M | $74.13M | $82.22M | $88.80M | $84.93M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$123.96M | -$173.13M | -$218.41M | -$207.49M | $218.88M |
| Capital expenditure | -$2.41M | -$2.44M | -$9.96M | -$30.72M | -$84.17M |
| Free cash flow | -$126.38M | -$175.56M | -$228.37M | -$238.21M | $134.70M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RGNX | $8.17 | +7.6% | 850.99K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |